BOLT.US Bolt Biotherapeutics

Healthcare Biotechnology USA Stocks
6.08 USD
Close of Nov 14, 2026
3.10 7.78
Market cap
USD 14.3M
P/E
-
P/B
1.10x
ROE
-301.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BOLT.US undervalued?

Graham number

The Graham number of Bolt Biotherapeutics cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bolt Biotherapeutics fundamental analysis

No fundamental analysis for Bolt Biotherapeutics yet.

Bolt Biotherapeutics stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company offers product candidates and platform technologies, including PRA-216, BDC-4182, a Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment o…

Full company profile